Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes.
about
Parkinson's disease: gene therapiesE Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV EvolutionStructure of neurotropic adeno-associated virus AAVrh.8.AAV's anatomy: roadmap for optimizing vectors for translational successA NEW RECOMBINANT ADENO-ASSOCIATED VIRUS (AAV)-BASED RANDOM PEPTIDE DISPLAY LIBRARY SYSTEM: INFECTION-DEFECTIVE AAV1.9-3 AS A NOVEL DETARGETED PLATFORM FOR VECTOR EVOLUTION.Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors.Biomathematical description of synthetic peptide libraries.The AAV vector toolkit: poised at the clinical crossroadsExamining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapyEngineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectorsHumoral Immune Response to AAV.An emerging adeno-associated viral vector pipeline for cardiac gene therapyAAV Vectors Vaccines Against Infectious Diseases.AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon.Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery VectorsPre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors.Bioethical conflicts of gene therapy: a brief critical review.Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune TargetingSystemic delivery of adeno-associated viral vectors.Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer.Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.Advancements in the design and scalable production of viral gene transfer vectors.
P2860
Q26824184-63BC8549-E148-4DDD-A14A-DAE0D6BFDDA8Q28083324-A82B926B-8E81-4078-BD4C-8ED601C47A12Q30152836-986A51A8-9528-4F81-97EF-2AAB43FC769EQ33659389-7EFF5411-7381-49F4-9AB7-614E94A79EB5Q33908400-104B7E93-BE98-4E01-A230-893D63C1540DQ34069571-76575AA0-052E-414A-99B9-3AEBEAD93DE7Q34370111-DD6BB5A6-D241-4BFF-8D1A-261BA4220307Q35649591-CE16EF2D-0917-4AE6-B07D-877B7DACFC74Q35652428-DDEDD6E5-45C6-46F3-9B96-DEC9286FDFEEQ35876224-D5DCE2C4-39C2-4DFB-A9AF-CAE20536620CQ35960506-9AE63DB5-EEAE-4B62-83A7-E6CF3596A2EAQ36171820-A5079A15-3F07-458F-A5B3-021010F98F76Q37066314-5309CD2C-9CCA-4E92-B067-64E82280C407Q37075772-DDEEEFD2-3390-4CCA-99D5-82252E766B3EQ37236099-52F85B47-13B9-4848-9475-F9B1008F2673Q37272838-C7A604EA-B364-4C98-8A5A-1FFA2681F163Q37498000-756CD8B4-3956-48EC-B5B5-8AE2C291BAE2Q37825907-D9A40923-1897-48E2-B321-9E48A336E2CCQ37937458-DF82CD59-8515-4E05-930D-294498CC40AAQ38187651-77F17D22-23AA-42C5-9DE5-1667302FCC87Q38191212-E7C2402B-54E3-4D35-980D-9A9E33686D1EQ38343860-3A8A58B1-6838-4193-8733-0DE2C77011CFQ38874937-4E4E5AE1-A611-4E7A-84AA-9C6E1C41E5BBQ38908933-3F4007CA-E7E5-4E64-A9AF-92E83274DA17Q39409371-5FFAFCEB-28AD-4C98-AD74-048183BFE9D2Q40097321-F529F0B9-FAAC-40D8-ACBE-48C26B97D194Q40212331-F182C6B9-5B5B-4523-B0DB-45CBFF1A42F3Q41931475-E3AB0141-FB2D-4AD0-9B3B-4858CC53DF53
P2860
Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Optimization of stealth adeno- ...... ation of immunogenic epitopes.
@ast
Optimization of stealth adeno- ...... ation of immunogenic epitopes.
@en
type
label
Optimization of stealth adeno- ...... ation of immunogenic epitopes.
@ast
Optimization of stealth adeno- ...... ation of immunogenic epitopes.
@en
prefLabel
Optimization of stealth adeno- ...... ation of immunogenic epitopes.
@ast
Optimization of stealth adeno- ...... ation of immunogenic epitopes.
@en
P2093
P1433
P1476
Optimization of stealth adeno- ...... ation of immunogenic epitopes.
@en
P2093
Anke Huber
Hildegard Büning
Luca Perabo
Stephan Maersch
P304
P356
10.1016/J.VIROL.2009.10.021
P407
P577
2009-11-18T00:00:00Z